Publications

Kim B, Shin J, Wu J, Omstead DT, Kiziltepe T, Littlepage LE, Bilgicer B. (2020) Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy. J Control Release. Apr 8;322:530-541. doi: 10.1016/j.jconrel.2020.04.010. [Epub ahead of print] PMID: 32276005

Xiao L, Wang C, Dai CLittlepage L, Li J, Schultz Z. (2019) Untargeted Tumor Metabolomics with Liquid Chromatography-Surface-Enhanced Raman Spectroscopy. Angew Chem Int Ed Engl. doi: 10.1002/anie.201912387. [Epub ahead of print] PMID: 31765069

Wang,C, Xiao, L, Dai, C, Nguyen, A, Littlepage, LE, Zachary Schultz, Jun Li. “A Statistical Approach of Background Removal and Spectrum Identification for SERS Data” Scientific Reports 2020;10(1):1460. Published 2020 Jan 29. doi:10.1038/s41598-020-58061-z PMID: 31996718

Romero-Moreno, R, Curtis, KJ, Coughlin, TR, Miranda-Vergara, MC, Dutta, S, Jackson, K, Li, J, Kaliney, W, Niebur, GL, and Littlepage, LE. “The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis” Nature Communications 2019 Sep 27;10(1):4404. doi: 10.1038/s41467-019-12108-6. PMID: 31562303

Ni Y, Schmidt KR, Werner BA, Koenig JK, Guldner IH, Schnepp PM, Tan X, Jiang L, Host M, Sun L, Howe EN, Wu J, Littlepage, LE, Nakshatri, H, and Zhang, S. “Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. Nat Commun. 2019 Jun 28;10(1):2860. doi: 10.1038/s41467-019-10743-7. PMID: 31253784

Breuer, EK, Fukushiro-Lopes, D, Dalheim, A, Burnette, M, Zartman, J, Kaja, S, Wells, C, Campo, L, Curtis, KJ, Romero-Moreno, R, Littlepage, LE, Niebur, GL, Hoskins, K, Nishimura MI, Gentile, S. “Stimulation of Kv11.1 potassium channel activity arrests breast cancer metastasis” Cell Death Dis. 2019 Feb 21;10(3):180. doi: 10.1038/s41419-019-1429-0. PMID: 30792401

Dai, C, Arceo, J, Arnold, J, Sreekumar, A, Dovichi, N, Li, J, Littlepage, LE. “Metabolomics of oncogene-specific metabolic reprogramming during breast cancer.Cancer & Metabolism (2018) Apr 3;6:5. doi: 10.1186/s40170-018-0175-6. eCollection 2018. PMID: 29619217

Takai, K, Drain, AP, Lawson, DA, Littlepage, LE, Karpuj, M, Kessenbrock, K, Le, A, Inoue, K, Weaver, VM, and Werb, Z. “Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers” Genes & Dev. 2018 Feb 1;32(3-4):244-257. doi: 10.1101/gad.301366.117. Epub 2018 Feb 26. PMID: 29483153.

Coughlin, TR, Romero-Moreno, R., Mason, D.E., Nystrom, L., Boerckel, J.D., Niebur, GL, and Littlepage, LE. “Bone: A Fertile Soil for Cancer Metastasis” Current Drug Targets. (2017) 18(11):1281-1295. doi: 10.2174/1389450117666161226121650. PMID: 28025941

Sawe RT, Mining SK, Ofulla AV, Patel K, Guyah B, Chumba D, Prosperi JR, Kerper M, Shi Z, Sandoval-Cooper M, Taylor K, Badve S, Stack MS, Littlepage LE. (2017) “Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya” Tropical Medicine and Health, Trop Med Health. 2017 Aug 4;45:19. doi: 10.1186/s41182-017-0059-4. eCollection 2017. PMID: 28794686

Suarez, CD, Badve, SS, Sparano, JA, Kaliney, W, Littlepage, LE. “The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance” Oncotarget. 2017 Jul 17;8(65):108534-108547. doi: 10.18632/oncotarget.19308. eCollection 2017 Dec 12. PMID: 29312549

Coughlin, TR, Romero-Moreno, R., Mason, D.E., Nystrom, L., Boerckel, J.D., Niebur, GL, and Littlepage, LE. (2016) “Bone: A Fertile Soil for Cancer Metastasis” Current Drug Targets. (In Press)

Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. (2016) Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. Sep 26. PMID:27669441

Sawe, RT, Kerper, Badve, S, Li, J, Sandoval-Cooper, M, Xie, S, Shi, Z, Patel, K, Chumba, D, Properi, JR, Taylor, K, Stack, S, Mining, SK, Littlepage, LE. (2016) “Breast cancer in western Kenya is aggressive with early onset, high proliferation, and immune cell infiltration with suppression of the adaptive immune response” BMC Cancer. Mar 10;16(1):204. PMID: 26964534

Suarez, CD and Littlepage, LE. (2016) “Patient-Derived Tumor Xenograft Models of Breast Cancer” Methods Mol Biol.;1406:211-23. PMID: 26820959

Frietze S*, O’Geen H*, Littlepage LE, Simion C*, Sweeney CA*, Farnham PJ*, Krig SR*. (2014) Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha. BMC Genomics. Jun 24;15:520. PMID: 24962896

Kessenbrock K*, Dijkgraaf GJ*, Lawson DA*, Littlepage LE, Shahi P*, Pieper U*, Werb Z.* (2013) A Role for Matrix Metalloproteinases in Regulating Mammary Stem Cell Function via the Wnt Signaling Pathway. Cell Stem Cell. Sep 5;13(3):300-13. Epub 2013 Jul 18. PMID: 23871604 (Kessenbrock and Dijkgraaf are joint first authors.)

Littlepage, L.E., Adler, A.S., Kouros-Mehr, H., Huang, G., Chou, J., Krig, S.R., Griffith, O.L., Korkola, J.E., Qu, K., Lawson, D.A., Xue, Q., Sternlicht, M.D., Dijkgraaf, G.J.P., Yaswen, P., Rugo, H.S., Sweeney, C.A., Collins, C.C., Gray, J., Chang, H.Y., Werb, Z. (2012) “The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression” Cancer Discovery; Jul;2(7):638-51. Epub 2012 May 10.

Littlepage, LE, Sternlicht, MD, Rougier, N, Phillips, J, Gallo, E, Yu, Y, Williams, K, Brenot, A, Gordon, J, Werb, Z (2010) Matrix Metalloproteinases Contribute Distinct Roles in Neuroendocrine Prostate Carcinogenesis, Metastasis, and Angiogenesis Progression. Cancer Res. Mar 15;70(6):2224-34. Epub 2010 Mar 9.

Kouros-Mehr, H, Bechis, SK, Slorach, EM, Littlepage, LE, Egeblad, M, Ewald, AJ, Pai, SY, Ho, IC, Werb, Z  (2008) GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell. Feb;13(2):141-52.

Adler, AS, Littlepage, LE, Lin, M, Kawahara, TLA, Wong, DJ, Liu, H, Werb, Z, Chang , HY (2008) CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Res. Jan 15;68(2):506-15.

Egeblad, M, Littlepage, LE, Werb, Z (2005) The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol. 2005;70:383-8. Review.

Radisky, DC, Levy, DD, Littlepage, LE, Liu, H, Nelson, CM, Fata, JE, Leake, D, Godden, EL, Albertson, DG, Nieto, MA, Werb, Z, Bissell, MJ (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. Jul 7; 436(7047): 123-7.

Littlepage, LE, Egeblad, M, Werb, Z (2005) Coevolution of cancer and stromal cellular responses. Cancer Cell. Jun; 7(6): 499-500.

Crane, R, Gadea, B, Littlepage, L, Wu, H, Ruderman, JV (2004) Aurora A, meiosis and mitosis. Biol Cell. Apr; 96(3):215-29. Review.

Littlepage, LE, Wu, H, Andresson, T, Deanehan, JK, Amundadottir, L, Ruderman, JV (2002) Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proc Natl Acad Sci U S A. Nov 26; 99(24): 15440-5.

Littlepage, LE and Ruderman, JV (2002) Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes & Dev. Sept. 1; 16(17): 2274-85.

Huang, JN, Park, I, Ellingson, E, Littlepage, LE, Pellman, D (2001) Activity of the APC (Cdh1) form of the anaphase-promoting complex persists until S phase and prevents the premature expression of Cdc20p.  J Cell Biol. Jul 9; 154(1): 85-94.

Mendez, R, Hake, LE, Andresson, T, Littlepage, LE, Ruderman, JV, Richter, JD (2000) Phosphorylation of CPE binding factor by Eg2 regulates translation of c-mos mRNA. Nature. 404(6775): 302-7.

Pasternack, LB, Littlepage, LE, Laude, DA, Appling, DR (1996) 13C NMR analysis of the use of alternative donors to the tetrahydrofolate-dependent one-carbon pools in Saccharomyces cerevisiaeArch. Biochem. Biophys. 326(1): 158-165.